• Mashup Score: 0

    Alicia Morgans engages with Silke Gillessen to discuss the upcoming APCCC conference in 2024. The conference seeks to address some of the major questions in clinical practice such as the management of biochemical relapse after radical prostatectomy and the application of novel endocrine agents plus PARP inhibitors in first line mCRPC treatments. Side effects and their management, especially…

    Tweet Tweets with this article
    • Navigating the future of #ProstateCancer treatment and #Global access at #APCCC24. @Silke_Gillessen @iosilab and @CaPsurvivorship @DanaFarber discuss the next @APCCC_Lugano conference 25-27 April 2024 addressing major questions in #clinicalpractice > https://t.co/XY9LI90TAa https://t.co/RFPosXkQTS

  • Mashup Score: 0

    As the premier virtual health event for the spondyloarthritis community, the 5th Annual Global Spondyloarthritis Summit features renowned rheumatologists and other health experts who provide the most up-to-date findings, medically reliable, and comprehensive information on essential topics that matter to those living with the disease. Whether you are newly diagnosed or have been living with the disease for years, the Summit is your opportunity to learn tips and tools for managing your symptoms while also

    Tweet Tweets with this article
    • Experience the groundbreaking 2023 #Global #Spondyloarthritis Summit! Enjoy invaluable insights from twelve presentations & engaging Day 2 Q&A sessions. Limited time only: Access for free until September 30, 2023. Watch now: https://t.co/QF5k4WZoMF #GlobalSummit #Spondysumit https://t.co/rdSfgKID2V

  • Mashup Score: 16

    An ongoing series led by Dr. Mrinal Gounder of MSK and Dr. Sewanti Limaye of Sir HN Reliance Foundation Hospital in Mumbai Interpreting results from next-generation genomic sequencing of cancer, and identifying the right drug for the right patient, is a challenge for many cancer specialists today. Join leading global experts for a new educational series from MSK, where we’ll take a deep dive into each of the major cancer signaling pathways and discuss the nuances of precision therapies—with the aim of

    Tweet Tweets with this article
    • Happening in a few hours! Don’t miss this unique Molecular Tumor Board with a MEK focus #Global Hosted by @MSKCancerCenter and @RFhospital , Mumbai India. Experts from MSKCC, Turkey, India and RFH! Free registration https://t.co/wh8jq62dOh https://t.co/vEIwYoqWFv

  • Mashup Score: 1
    Resources page - 7 month(s) ago

    This edition of the Evidence Based Nursing (EBN) resources page is focused on further information to support the editorial by Alison Twycross and Jane Wray ‘NHS (National Health Service (NHS) England Long-term Workforce Plan: Can this deliver the workforce transformation so urgently needed or is it just more rhetoric?’ EBN has published a number of commentaries that provide useful additional information relating to the UK NHS workforce.

    Tweet Tweets with this article
    • Check out our Resources Page for July 2023 by @livinghope and explore our comprehensive collection of commentaries, blogs, and resources focused on the UK NHS and global workforce 🌍 #Healthcare #Global #Workforce 🔎 Find more here: https://t.co/jFyDAV4dOn https://t.co/s3dthuMbiY

  • Mashup Score: 0

    Alicia Morgans engages with Silke Gillessen to discuss the upcoming APCCC conference in 2024. The conference seeks to address some of the major questions in clinical practice such as the management of biochemical relapse after radical prostatectomy and the application of novel endocrine agents plus PARP inhibitors in first line mCRPC treatments. Side effects and their management, especially…

    Tweet Tweets with this article
    • Navigating the future of #ProstateCancer treatment and #Global access at #APCCC24. @Silke_Gillessen @iosilab and @CaPsurvivorship @DanaFarber discuss the next @APCCC_Lugano conference 25-27 April 2024 addressing major questions in #clinicalpractice > https://t.co/XY9LI90lKC https://t.co/nW8St0EhCO

  • Mashup Score: 5

    This interactive tool demonstrates data from the Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021, which reports the magnitude of total CVD burden, including by disease state and risk factors across 21 global regions. This tool demonstrates the data in three sections: Total CVD mortality rates by region Mortality rates by CV disease state Risk factors, location metrics & socioeconomic data Explore each of these interactive settings to delve into these important global data. Published by the Global Burden of CVD Collaboration—an alliance between JACC, the Institute for Health Metrics and Evaluation, and the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2022 Dec, 80 (25) 2372–2425.

    Tweet Tweets with this article
    • Dr. Gregory Roth (@IHME) highlights the Global Burden of #CVD interactive resource on @JACCJournals at #ESCCongress. 🌎 Explore data rich visualization from across 21 regions here: https://t.co/OQTdPyZ9ac #GBDStudy #JACC #CardioTwitter https://t.co/3nHCI1MqAe

    • .#ESCCongress2023: Live now. Insightful JACC Joint session. Location: Hub Mondrian. #Global burden of #CVD & risks: what should #European cardiovascular clinicians do? Also check out the #GBDStudy interactive tool: #JACC #NHLBI #IHME. https://t.co/b8iSqaRBPY #ESCCongress #cvPrev https://t.co/f0maHOsS2P

  • Mashup Score: 0

    Alicia Morgans engages with Silke Gillessen to discuss the upcoming APCCC conference in 2024. The conference seeks to address some of the major questions in clinical practice such as the management of biochemical relapse after radical prostatectomy and the application of novel endocrine agents plus PARP inhibitors in first line mCRPC treatments. Side effects and their management, especially…

    Tweet Tweets with this article
    • Navigating the future of #ProstateCancer treatment and #Global access at #APCCC24. @Silke_Gillessen @iosilab and @CaPsurvivorship @DanaFarber discuss the next @APCCC_Lugano conference 25-27 April 2024 addressing major questions in #clinicalpractice > https://t.co/XY9LI90lKC https://t.co/A6qgXkxzkC